Galecto Acquires AML Asset from Bridge Medicines, Inc.

Sanders TDI congratulates Galecto, Inc. who just announced their recent acquisition of the global rights to BRM-1420, a small molecule from Bridge Medicines, Inc. that was derived from a Sanders TDI compound! Galecto plans to file an IND in late 2025 or early 2026 for certain oncology applications, including acute myeloid leukemia.

This ENL-YEATS drug discovery project originated in the lab of the late Dr. C. David Allis at The Rockefeller University. The Allis lab, including Dr. Liling Wang (now at the University of Pennsylvania), worked in close collaboration with researchers from Sanders TDI to eliminate the “valley of death” that exists between academic discovery and industrial drug development. Without this type of expert assistance in navigating the path of drug discovery, even the most transformational research advances often do not realize their potential to become major medical breakthroughs.

Sanders TDI celebrates all the researchers and their hard work and dedication in moving this oncology project closer to patients with significant unmet medical needs.